Clinical Trial Update: Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD [Phase 3]

View source ↗

Summary

Phase 3 trial results for the Methylphenidate Transdermal System (MTS) in adolescents with ADHD completed, with safety and efficacy data reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Methylphenidate Transdermal System (methylphenidate)

Snippet

Sponsor: Noven Therapeutics | Conditions: ADHD | Phase 3 | Status: COMPLETED | Results posted: 2010-01-15